FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Equine veterinary journal2003; 35(4); 407-413; doi: 10.2746/042516403776014226

Tiludronate as a new therapeutic agent in the treatment of navicular disease: a double-blind placebo-controlled clinical trial.

Abstract: Bisphosphonates, such as tiludronate, are used to normalise bone metabolism via inhibition of bone resorption. Areas of increased bone resorption and formation are typical lesions in a diseased navicular bone. Objective: To determine if bone remodelling changes occurring in navicular disease may be corrected with therapies regulating bone metabolism. Methods: We designed a double-blind, placebo-controlled clinical trial to compare 2 doses of tiludronate, 0.5 mg/kg and 1 mg/kg bwt administered via daily i.v. injections over 10 days for the treatment of navicular disease. Seventy-three horses, split into 2 subpopulations of recent and chronic cases, were enrolled to be followed-up over 6 months. Of these, 33 recent and 17 chronic cases meeting the selection criteria were maintained in the final efficacy analyses. Clinical examinations were videorecorded and reviewed blindly by an independent expert. Results: Horses treated with the higher dose showed optimal improvement of lameness and return to normal level of activity 2-6 months post treatment. The more recent the onset of clinical signs at the time of treatment, the greater the efficacy. The treatment did not modify the response to extension and flexion tests. The lower dose failed to significantly improve the condition. Conclusions: Tiludronate efficacy is demonstrated in the treatment of navicular disease at the dose of 1 mg/kg bwt. Conclusions: Our results support the clinical relevance of bone remodelling changes in the outcome of navicular disease.
Get Full Text
Publication Date: 2003-07-26 PubMed ID: 12880010DOI: 10.2746/042516403776014226Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Clinical Trial
  • Journal Article
  • Randomized Controlled Trial

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study evaluates the effectiveness of Tiludronate, a bisphosphonate medication used to regulate bone metabolism, in treating navicular disease in horses. The research indicates that higher doses of Tiludronate lead to significant improvement in lameness symptoms and restore normal activity levels within 2-6 months.

Study Subjects and Methodology

  • The researchers conducted a double-blind, placebo-controlled clinical trial to compare the effects of 0.5 mg/kg and 1 mg/kg doses of Tiludronate administered via daily intravenous injections over a 10-day period.
  • 73 horses, categorised into two groups based on the duration of their illness (recent or chronic), were initially selected to participate.
  • However, only 33 recent and 17 chronic cases that met the selection criteria were included in the final analysis.
  • The horses’ condition was assessed over a 6-month follow-up period. Their clinical examinations were video-recorded and reviewed by an independent expert who was not privy to the treatment details (double-blind).

Key Findings

  • The research found that horses treated with the higher dose (1 mg/kg) showed substantial improvement in their lameness conditions and returned to their previous activity levels between 2-6 months after treatment.
  • The study also found out that the quicker the treatment was started after the initial onset of symptoms, the greater the efficacy of the treatment.
  • This treatment, however, did not alter the horses’ responses to extension and flexion tests.
  • The lesser dose of 0.5 mg/kg was not found to significantly improve the condition of the horses.

Conclusions

  • Implications of the study show that Tiludronate effectively treats navicular disease at a dosage level of 1 mg/kg body weight.
  • The researchers also observe that the changes in bone remodelling have a significant clinical impact on the outcome of navicular disease.

Cite This Article

APA
Denoix JM, Thibaud D, Riccio B. (2003). Tiludronate as a new therapeutic agent in the treatment of navicular disease: a double-blind placebo-controlled clinical trial. Equine Vet J, 35(4), 407-413. https://doi.org/10.2746/042516403776014226

Publication

Equine veterinary journal
ISSN: 0425-1644
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 35
Issue: 4
Pages: 407-413

Researcher Affiliations

Denoix, J M
  • CIRALE/ENVA IPC, Goustranville, 14430 Dozulé, France.
Thibaud, D
    Riccio, B

      MeSH Terms

      • Animals
      • Bone Resorption / drug therapy
      • Bone Resorption / veterinary
      • Diphosphonates / therapeutic use
      • Dose-Response Relationship, Drug
      • Double-Blind Method
      • Female
      • Foot Diseases / drug therapy
      • Foot Diseases / veterinary
      • Hoof and Claw
      • Horse Diseases / drug therapy
      • Horses
      • Injections, Intravenous / veterinary
      • Lameness, Animal / drug therapy
      • Male
      • Osteitis / drug therapy
      • Osteitis / veterinary
      • Treatment Outcome
      • Video Recording

      Citations

      This article has been cited 15 times.
      1. Conrad MB, Leatherwood JL, Paris BL, George JM, Martinez RE, Vergara-Hernandez FB, Nielsen BD, Colbath AC, Arnold CE, Glass KG, Welsh TH Jr, Bradbery AN. Effects of clodronate disodium on endocrine regulators of calcium in yearling horses. J Anim Sci 2025 Jan 4;103.
        doi: 10.1093/jas/skaf132pubmed: 40259552google scholar: lookup
      2. Tippen SP, Metzger CE, Sacks SA, Allen MR, Mitchell CF, McNulty MA. Clinically relevant doses of tiludronate do not affect bone remodelling in pasture-exercised horses. Equine Vet J 2025 Mar;57(2):513-521.
        doi: 10.1111/evj.14119pubmed: 38924597google scholar: lookup
      3. Reis IL, Lopes B, Sousa P, Sousa AC, Caseiro AR, Mendonça CM, Santos JM, Atayde LM, Alvites RD, Maurício AC. Equine Musculoskeletal Pathologies: Clinical Approaches and Therapeutical Perspectives-A Review. Vet Sci 2024 Apr 26;11(5).
        doi: 10.3390/vetsci11050190pubmed: 38787162google scholar: lookup
      4. Vergara-Hernandez FB, Nielsen BD, Popovich JM Jr, Panek CL, Logan AA, Robison CI, Ehrhardt RA, Johnson TN, Chargo NJ, Welsh TH Jr, Bradbery AN, Leatherwood JL, Colbath AC. Clodronate disodium does not produce measurable effects on bone metabolism in an exercising, juvenile, large animal model. PLoS One 2024;19(4):e0300360.
        doi: 10.1371/journal.pone.0300360pubmed: 38626145google scholar: lookup
      5. Wilcox CV, Knych HK, Katzman SA, Arthur RM, Rodriguez V, Finno CJ. Effect of clodronate on gene expression in the peripheral blood of horses. J Vet Pharmacol Ther 2024 May;47(3):187-192.
        doi: 10.1111/jvp.13424pubmed: 38197553google scholar: lookup
      6. Vergara-Hernandez FB, Nielsen BD, Colbath AC. Is the Use of Bisphosphonates Putting Horses at Risk? An Osteoclast Perspective. Animals (Basel) 2022 Jul 3;12(13).
        doi: 10.3390/ani12131722pubmed: 35804621google scholar: lookup
      7. Osborn ML, Cornille JL, Blas-Machado U, Uhl EW. The equine navicular apparatus as a premier enthesis organ: Functional implications. Vet Surg 2021 May;50(4):713-728.
        doi: 10.1111/vsu.13620pubmed: 33710628google scholar: lookup
      8. Yu H, Yang H, Shi E, Tang W. Development and Clinical Application of Phosphorus-Containing Drugs. Med Drug Discov 2020 Dec;8:100063.
        doi: 10.1016/j.medidd.2020.100063pubmed: 32864606google scholar: lookup
      9. Mitchell A, Watts AE, Ebetino FH, Suva LJ. Bisphosphonate use in the horse: what is good and what is not?. BMC Vet Res 2019 Jun 24;15(1):211.
        doi: 10.1186/s12917-019-1966-xpubmed: 31234844google scholar: lookup
      10. Lacitignola L, Luca P, Santovito R, Comite MSD, Crovace A. Nutritional secondary hyperparathyroidism in two ponies. Open Vet J 2018;8(2):149-153.
        doi: 10.4314/ovj.v8i2.6pubmed: 29765869google scholar: lookup
      11. Richbourg HA, Mitchell CF, Gillett AN, McNulty MA. Tiludronate and clodronate do not affect bone structure or remodeling kinetics over a 60 day randomized trial. BMC Vet Res 2018 Mar 20;14(1):105.
        doi: 10.1186/s12917-018-1423-2pubmed: 29554967google scholar: lookup
      12. Mizobe F, Nomura M, Kato T, Nambo Y, Yamada K. Signal changes in standing magnetic resonance imaging of osseous injury at the origin of the suspensory ligament in four Thoroughbred racehorses under tiludronic acid treatment. J Equine Sci 2017;28(3):87-97.
        doi: 10.1294/jes.28.87pubmed: 28955160google scholar: lookup
      13. Hunter BG, Duesterdieck-Zellmer KF, Larson MK. Tiludronate concentrations and cytologic findings in synovial fluid after intravenous regional limb perfusion with tiludronate in horses. PeerJ 2015;3:e889.
        doi: 10.7717/peerj.889pubmed: 25945303google scholar: lookup
      14. Duesterdieck-Zellmer KF, Moneta L, Ott JF, Larson MK, Gorman EM, Hunter B, Löhr CV, Payton ME, Morré JT, Maier CS. Effects of low and high dose intraarticular tiludronate on synovial fluid and clinical variables in healthy horses-a preliminary investigation. PeerJ 2014;2:e534.
        doi: 10.7717/peerj.534pubmed: 25237596google scholar: lookup
      15. Delguste C, Doucet M, Gabriel A, Guyonnet J, Lepage OM, Amory H. Assessment of a bone biopsy technique for measuring tiludronate in horses: a preliminary study. Can J Vet Res 2011 Apr;75(2):128-33.
        pubmed: 21731184
      Subscribe to our newsletter
      Join 99,493 horse owners like you who receive our email updates on horse health and nutrition.